Evidence map›Paper›PMID 35745154›Full record

Observational studyNutrients2022

Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice.

Sarah Oddoux, Paul Violette, Jeanne Cornet, Julie Akkoyun-Farinez, Michel Besnier, Antoine Noël, Frédéric Rouillon

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah OddouxLaboratoire Dielen, 50110 Cherbourg-en-Cotentin, France.ORCID 0000-0002-2888-8430
Paul VioletteLaboratoire Dielen, 50110 Cherbourg-en-Cotentin, France.
Jeanne CornetEuraxi Pharma, 37300 Joué-lès-Tours, France.
Julie Akkoyun-FarinezEuraxi Pharma, 37300 Joué-lès-Tours, France.ORCID 0000-0001-5392-6331
Michel BesnierCentre Médical Thémis, 50100 Cherbourg-en-Cotentin, France.
Antoine NoëlLaboratoire Dielen, 50110 Cherbourg-en-Cotentin, France.
Frédéric RouillonHôpital Ste Anne, 75014 Paris, France.

Funding

Région Normandie 17P03672
6 · The paper itself

Abstract

Anxiety is a high frequency disorder in the general population. It is usually treated with benzodiazepines, which cause side effects and a dependence that could make withdrawal difficult. Alternative treatments are therefore needed to reduce the use of anxiolytics, particularly for adjustment disorder with anxiety. An observational, multicentre, prospective, longitudinal study has been conducted by general practitioners and one gynaecologist to evaluate the efficacy of a dietary supplement on adjustment disorder with anxiety (Stress 2 study). Patients diagnosed as anxious with a score of ≥20 on the Hamilton Anxiety Rating Scale (Ham-A, first visit on Day 0 (V0)) were offered a 28-day treatment with a dietary supplement formulated with bioactive peptides from a fish protein hydrolysate (Gabolysat®), magnesium and vitamin B6. At the second visit (V1), the Ham-A Rating Scale, the Patient Global Impression scale (PGI) and the Clinical Global Impressions scale (CGI) were administered. A 50% reduction in the Ham-A score, was achieved for 41.9% of the patients. The mean Ham-A score decreased by 12.1 ± 5.7 points (p < 0.001) between V0 (25.6 ± 3.8) and V1 (13.6 ± 6.0). Furthermore, according to the CGI scale, the anxiety of 75.3% of patients improved significantly and very significantly, with limited side effects and a negligible rebound effect. In conclusion, adjustment disorder with anxiety seems to be effectively managed by an alternative and safer solution than benzodiazepines.

Indexed as

Adjustment DisordersGeneral PracticeAnxietyBenzodiazepinesDietary SupplementsHumansLongitudinal StudiesMagnesiumPeptidesProspective StudiesPsychiatric Status Rating ScalesTreatment OutcomeBenzodiazepinesMagnesiumPeptidesanxietybioactive peptidedietary supplementmagnesiumstress

Identifiers

PMID35745154
PMCPMC9228954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.